The present invention relates to the construction and application of a fusion protein vaccine platform. The present invention provides a vaccine, comprising a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope. The present invention also relates to use of a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope in the preparation of prophylactic or therapeutic compositions. The vaccine of the present invention can be produced by eukaryotic cell expression systems to prepare wild-type and various mutant antigen vaccines, and vaccination by means of subcutaneous/muscular or nasal or other routes can lead to a strong immune response to a body. The vaccine of the present invention can be used as a prophylactic or therapeutic vaccine.

The present invention includes compositions and methods that utilize a Universal Immune Receptor (UnivIR) CAR system comprising a modified T cell comprising a DOTA CAR and a DOTA-conjugated targeting ligand. In certain embodiments, the invention includes methods for treating, ameliorating, and/or preventing cancer. In certain embodiments, the invention provides a set of complementary molecular imaging tools that is applicable to CAR T cell therapy.

Embodiments of the disclosure include methods and compositions useful for treating cancer in an immunogenic manner so as to elicit local tumor regression, while priming systemic immunity. In one embodiment, there is expansion of tumor-specific immune cells through administration of fibroblasts, either natural or modified in an intratumoral and/or peritumoral manner. In other embodiments, manipulation of a local tumor microenvironment is achieved by injections of immune-modulating fibroblasts to facilitate expansion of immune effector cells, which are subsequently re-stimulated in the periphery by antigenic exposure. In another embodiment, agents are provided that allow for systemic derepression of immunity, while optionally augmenting ability of immune effector cells to expand and kill tumor cells.

This document relates to methods and materials involved in treating a mammal (e.g., a human) having, or at risk of developing, a disease or a condition characterized by inflammation and/or degeneration of a tissue. For example, mesenchymal stem cells (MSCs) expressing an antigen receptor (e.g., a chimeric antigen receptor) targeting a tissue that can exert an immunosuppressive effect in the targeted tissue as well as methods for using such MSCs are provided herein.

The present invention relates to RNA, particularly an immunostimulatory RNA (isRNA), a coding RNA or a combination thereof, for use in the treatment or prophylaxis of a disease, in particular a tumor and/or cancer disease. The present invention also provides pharmaceutical compositions, and a kit comprising the RNA(s). Further, the invention also comprises medical uses of the RNA(s) and compositions comprising the RNA(s).

Provided is a modified immune cell, comprising a chimeric antigen receptor and/or a coding element therefor, or comprising a T cell receptor and/or a coding element therefor. The immune cell further comprises: leptin and/or a functional fragment thereof; and/or, a leptin receptor and/or a functional fragment thereof, and the expression quantity of the leptin receptor and/or the functional fragment thereof in the immune cell is increased compared with that in an immune cell without the corresponding modification. In addition, also provided is another modified immune cell, comprising leptin and/or a functional fragment thereof, and/or, a leptin receptor and/or a functional fragment thereof, and a low-density lipoprotein-receptor-related protein or a fragment thereof.

A method for coupling an antibody to a surface of a cell comprises the following steps: (1) chemically modifying sialic acid to obtain a sialic acid derivative containing an azide group; (2) absorbing the sialic acid derivative by the cell to obtain a cell modified with the azide group; (3) modifying the antibody with a conjunction compound to obtain a modified antibody; (4) co-culturing the modified antibody with the cell modified with the azide group. The present disclosure modifies natural sialic acid molecules in vitro through chemical synthesis methods, and utilizes modified natural sialic acid molecules to realize antibody modification on the surface of the cell. The modification method of the present disclosure is simple, low-cost, safe, and efficient, does not need complex gene editing or enzyme catalytic operation, and has universality. In theory, the modification method can realize the coupling of any antibody or macro-molecular substance on the surface of the cell.

The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified equine encephalitis virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating cancer.

Described herein are compositions and methods for treating cancer and autoimmune diseases.

Compositions are provided according to aspects of the present invention that include a hydrogel and a liner, wherein a surface of the hydrogel dissociably-engages a surface of the liner. Compositions are provided according to aspects of the present invention that include a hydrogel and a hydrophobic glue, wherein at least a portion of the gel network of the hydrogel is occupied by the hydrophobic glue. Reverse coaling processes and articles of manufacture made by reverse coating processes are provided according to aspects of the present invention. Compositions are provided according to aspects of the present invention that include a hydrogel and a substrate, wherein: the hydrogel comprises a polymer network; the substrate comprises a surface comprising a polymer network; and the polymer network of the hydrogel and the polymer network of the surface are entangled.